1. Cell Cycle/DNA Damage PI3K/Akt/mTOR Apoptosis
  2. DNA-PK Apoptosis
  3. DNA-PK-IN-16

DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8+ T cells in tumor tissues through synergistic action with anti-PD-L1 monoclonal antibody. DNA-PK-IN-16 is applicable for cancer research.

For research use only. We do not sell to patients.

DNA-PK-IN-16

DNA-PK-IN-16 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DNA-PK-IN-16 is an orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 10.2 nM. DNA-PK-IN-16 induces the upregulation of γH2A.X, a biomarker of DNA double-strand breaks. DNA-PK-IN-16 exhibits antiproliferative activity in various cancer cell lines. DNA-PK-IN-16 enhances the infiltration of CD8+ T cells in tumor tissues through synergistic action with anti-PD-L1 monoclonal antibody. DNA-PK-IN-16 is applicable for cancer research[1].

In Vitro

DNA-PK-IN-16 (compound D11) (48 h) potently inhibits the proliferation of LoVo, B16-F10, Jurkat, HL-60, MDA-MB-436 and MDA-MB-231 cancer cells, with IC50 values ranging from 1.6 to 6.9 μM[1].
DNA-PK-IN-16 (1-10 μM; 24 h) upregulates the expression of γH2A.X in a concentration-dependent manner in Bleomycin (HY-108345)-treated LoVo cells, indicating impaired DNA damage repair function[1].
DNA-PK-IN-16 (1-10 μM; 24 h) dose-dependently induces apoptosis in LoVo cells, reduces mitochondrial membrane potential, disrupts cell cycle progression, and inhibits cell migration[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: LoVo, B16-F10, Jurkat, HL-60, MDA-MB-436, MDA-MB-231 cancer cell lines
Concentration: /
Incubation Time: 48 h
Result: Exhibited robust antiproliferative activity across all six cell lines, with IC50 values of 1.6 μM (LoVo), 5.3 μM (B16-F10), 1.9 μM (Jurkat), 2.1 μM (HL-60), 3.6 μM (MDA-MB-436), and 6.9 μM (MDA-MB-231).

Cell Cycle Analysis[1]

Cell Line: LoVo cells
Concentration: 1, 5, 10 μM
Incubation Time: 24 h
Result: Dose-dependently decreased the proportion of cells in the G2/M phase and increased the proportion of cells in the S phase.
Parmacokinetics
Species Dose Route AUC0-t AUC0-∞ T1/2 CL C0 Cmax Bioavailability
Rat[1] 2 mg/kg i.v. 1198.4 μg/L·h 2084.8 μg/L·h 36.1 h 1.2 L/h/kg 625.3 μg/L / /
Rat[1] 20 mg/kg p.o. 8398.4 μg/L·h 8898.4 μg/L·h 50.0 h 8.8 L/h/kg / 1404.3 μg/L 42.6 %
In Vivo

DNA-PK-IN-16 (25-50 mg/kg; p.o.; once daily; 15 days) dose-dependently inhibits the growth of LoVo colorectal cancer xenografts[1].
DNA-PK-IN-16 (50 mg/kg; p.o.; once daily) inhibits the growth of B16-F10 melanoma (49.2% TGI), and also synergizes with anti-PD-L1 monoclonal antibody to enhance antitumor efficacy by increasing CD8+ T cell infiltration (69.6% TGI), while maintaining favorable safety profiles[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (male, 6-8 weeks old, subcutaneously inoculated with LoVo cells)[1]
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.g.; once daily; 15 days
Result: Achieved a tumor growth inhibition (TGI) rate of 30.1% at 25 mg/kg.
Achieved a TGI rate of 72.9% at 50 mg/kg.
Downregulated Ki-67 and PCNA (cell proliferation markers) in a dose-dependent manner.
Upregulated TUNEL-positive apoptotic cells in a dose-dependent manner.
Enhanced γH2A.X signals (a marker of DNA double-strand breaks) in tumor tissues in a dose-dependent manner.
Caused no significant body weight loss or reduced food intake in mice during treatment.
Molecular Weight

456.54

Formula

C25H28N8O

SMILES

C1(C2=CN=C(N=C2)N3CCNCC3)=CC=C(C4=C1)N=CC5=C4N(C6CCOCC6)C7=NCCN57

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DNA-PK-IN-16
Cat. No.:
HY-181848
Quantity:
MCE Japan Authorized Agent: